medigraphic.com
ISSN 0016-3813 (Print)

2007, Number 5

<< Back Next >>

Gac Med Mex 2007; 143 (5)

Estrategias para el diagnóstico clínico y molecular de Charcot-Marie-Tooth 1A. Estudio en pacientes mexicanos

Edgar Hernández-Zamora, María de la Luz Arenas-Sordo, Rosa Elena Escobar-Cedillo, Norma Celia González-Huerta, Norberto Leyva-García, Rogelio Maldonado-Rodríguez

Language: Spanish
References: 55
Page: 383-389
PDF size: 156.43 Kb.


ABSTRACT

Background: Charcot-Marie-Tooth (CMT) is the most common inherited disorder of the human peripheral nerve. The most frequent subtype, CMT1A, is associated with duplication of ~1.5 Mb fragment in 17p11-p12, that includes the PMP22 gene. Objective: The aim of this study was to describe different strategies used for clinical and molecular CMT1A diagnoses among patients attending the National Rehabilitation Institute of Mexico (INR). Material and methods: 17 patients had clinical and electrophysiological features compatible with CMT1. A molecular study using capillary electrophoresis (CE) was performed and a PMP22 gene duplication was detected. Results: Clinical, biochemical and electrophysiological studies constituted the inclusion criteria to establish a CMT1diagnosis. With CE the duplication of the PMP22 gene was observable and we established a possible CMT1A diagnosis in seven patients. All duplications detected by capillary electrophoresis were corroborated using FISH. Conclusion: CE is a feasible and reliable method to detect PMP22 gene duplication. Using different clinical, electrophysiological and molecular strategies in this patient population allowed us to establish an accurate diagnosis and offer suitable genetic counseling.


REFERENCES

  1. Salamanca-Gómez F. Avances en el estudio de las enfermedades neurodegenerativas. Gac Med Mex 2001;137:487-488.

  2. Benstead TJ, Grant IA. Progress in clinical neurosciences: Charcot-Marie-Tooth disease and related inherited peripheral neuropathies. Can J Neurol Sci 2001;28:199-214.

  3. Sevilla T. Genética de la enfermedad de Charcot-Marie-Tooth tipo 1, de las neuropatías focales hereditarias y de las neuropatías hereditarias motoras distales. Rev Neurol 2000;30:71-79.

  4. Nodera H, Bostock H, Kuwabara S, Sakamoto T, Asanuma K, Jia-Ying S, et al. Nerve excitability properties in Charcot-Marie-Tooth disease type 1A. Brain 2004;127:203-211.

  5. Rodríguez-García PL, Rodríguez-Pupo L, Rodríguez-García D. Técnicas clínicas para el examen físico neurológico. I. Organización general, nervios craneales y nervios raquídeos periféricos. Rev Neurol 2004;39:757-766.

  6. Rodríguez-García PL, Rodríguez-Pupo L, Rodríguez-García D. Técnicas clínicas para el examen físico neurológico. II. Funciones motora y refleja. Rev Neurol 2004;39:848-859.

  7. Rodríguez-García PL, Rodríguez-Pupo L, Rodríguez-García D. Técnicas clínicas para el examen físico neurológico. III. Funciones sensoriales. Rev Neurol 2004;39:966-971.

  8. Amo-Usanos C, Martín-Jiménez S, Basurte-Villamor P, Puente-Muñoz AI, Amo-Merino P, Amo-Usanos I, et al. Sobre el diagnóstico de las neuropatías periféricas: estudio clínico y neurofisiológico. Rev Neurol 2001;32:123-126.

  9. Berghoff C, Berghoff M, Leal A, Morera B, Barrantes R, Reis A, et al. Clinical and electrophysiological characteristics of autosomal recessive axonal Charcot- Marie-Tooth disease (ARCMT2B) that maps to chromosome 19q13.3. Neuromuscul Disord 2004;14:301-306.

  10. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991;66:219-232.

  11. Hanemann CO, Stoll G, D’Urso D, Fricke W, Martin JJ, Van Broeckhoven C, et al. Peripheral myelin protein-22 expression in Charcot-Marie Tooth disease type 1a sural nerve biopsies. J Neurosci Res 1994;37:654-659.

  12. Marques WJ, Sweeney MG, Wood NW. Thr(118)Met amino acid substitution in the peripheral myelin protein 22 does not influence the clinical phenotype of Charcot-Marie-Tooth disease type 1A due to the 17p11.2- p12 duplication. Braz J Med Biol Res 2003;36:1403-1407.

  13. Suter U, Moskow JJ, Welcher AA, Snipes GJ, Kosaras B, Sidman RL, et al. A leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse. Proc Natl Acad Sci 1992;89:4382-4386.

  14. Suter U, Snipes GJ, Schoener-Scott R, Welcher AA, Pareek S, Lupski JR, et al. Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters. J Biol Chem 1994;269:25795-25808.

  15. Suter U, Welcher AA, Ozcelik T, Snipes GJ, Kosaras B, Francke U, et al. Trembler mouse carries a point mutation in a myelin gene. Nature 1992;356:241-244.

  16. Niemann S, Sereda MW, Suter U, Griffiths IR, Nave KA. Uncoupling of myelin assembly and schwann cell differentiation by transgenic overexpression of peripheral myelin protein 22. J Neurosci 2000;20:4120-4128.

  17. Chies R, Nobbio L, Edomi P, Schenone A, Schneider C, Brancolini C. Alterations in the Arf6-regulated plasma membrane endosomal recycling pathway in cells overexpressing the tetraspan protein Gas3/PMP22. J Cell Sci 2003;116:987-999.

  18. Sancho S, Young P, Suter U. Regulation of Schwann cell proliferation and apoptosis in PMP22-deficient mice and mouse models of Charcot-Marie-Tooth disease type 1A. Brain 2001;124:2177-2187.

  19. Robertson AM, Perea J, McGuigan A, King RH, Muddle JR, Gabreels- Festen AA, et al. Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A. J Anat 2002;200:377-390.

  20. Reiter LT, Murakami T, Koeuth T, Gibbs RA, Lupski JR. The human COX10 gene is disrupted during homologous recombination between the 24 kb proximal and distal CMT1A-REPs. Hum Mol Genet 1997;6:1595-1603.

  21. Cruz-Medina E, Soria-Batida MA. Resúmenes de los trabajos de investigación presentados en la XVI Jornadas Nacionales de Médicos Residentes en Medicina de Rehabilitación: Número de casos nuevos de enfermedades neuromusculares atendidos en el Centro Nacional de Rehabilitación y Ortopedia, Instituto Nacional de Neurología y Hospital Infantil de México. Rev Mex Med Fis Rehab 2000;12:6-9.

  22. Papazian O. Alfonso I, García F. Evaluación neurofisiológica de los niños con neuropatías periférica. Rev Neurol 2002;35:254-268.

  23. Dumitru D. Electrodiagnostic medicine. Philadelphia:Hanlel & Belfus, Inc.; 2001.

  24. DeLisa JA, Lee HJ, Baran EM, Lai KS, Spielholz. Manual of nerve conduction velocity and clinical neurophysiology. 3a. ed. New York: Raven Press; 1994.

  25. Szasz G, Gerhardt W, Gruber W. Creatine kinase in serum: 3. Further study of adenylate kinase inhibitors. Clin Chem 1977;23:1888-1892.

  26. Kasamatsu T. Studies on the serum aldolase activity in workers with muscle disorders caused by vibration work. Sangyo Igaku 1983;25:493-502.

  27. Amador E, Dorfman LE, Wacker WE. Serum lactic dehydrogenase activity: an analytical assessment of current assays. Clin Chem 1963;12:391-399.

  28. Wroblewski F, LaDue JS. Serum glutamic pyruvic transaminase in cardiac with hepatic disease. Proc Soc Exp Biol Med 1956;91:569-571.

  29. Saris NE. International Federation of Clinical Chemistry (IFCC). The role of the IFCC-section in Clinica Chimica Acta. Clin Chim Acta 1975;61:F1.

  30. Bowers GN J, McComb RB. Measurement of total alkaline phosphatase activity in human serum. Clin Chem 1975;21:1988-1995.

  31. Shaffer LG, Kennedy GM, Spikes AS, Lupski JR. Diagnosis of CMT1A duplications and HNPP deletions by interphase FISH: implications for testing in the cytogenetics laboratory. Am J Med Genet 1997;69:325-331.

  32. Verma RS, Babú A. Human chromosomes: Manual of basic techniques. New York: Pergamon Press; 1989. pp. 5-9.

  33. Buffone GJ, Darlington GJ. Isolation of DNA from biological specimens without extraction with phenol. Clin Chem 1985;31:164-165.

  34. Chamberlain JS, Gibbs RA, Ranier JE, Nguyen PN, Caskey CT. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res 1988;16:11141-11156.

  35. Chamberlain JS, Gibbs RA, Ranier JE, Caskey CT. Multiplex PCR for the diagnosis of Duchenne muscular dystrophy. EUA: Academic Press; 1990.

  36. Roa BB, García CA, Pentao L, Killian JM, Trask BJ, Suter U, et al. Evidence for a recessive PMP22 point mutation in Charcot-Marie-Tooth disease type 1A. Nat Genet 1993;5:189-194.

  37. Roa BB, García CA, Suter U, Kulpa DA, Wise CA, Mueller J, et al. Charcot-Marie-Tooth disease type 1A. Association with a spontaneous point mutation in the PMP22 gene. N Engl J Med 1993;329(2):96-101.

  38. Castagnino JM. Electroforesis capilar. Bioquimia 2000;25:13-32.

  39. Yau SC, Bobrow M, Mathew CG, Abbs SJ. Accurate diagnosis of carriers of deletions and duplications in Duchenne/Becker muscular dystrophy by fluorescent dosage analysis. J Med Genet 1996;33:550-558.

  40. Lynn AM, Jain CK, Kosalai K, Barman P, Thakur N, Batra H, et al. An automated annotation tool for genomic DNA sequences using GeneScan and BLAST. J Genet 2001;80:9-16.

  41. Pereira-Vianello BR, Grattapaglia D. Cost-effective method to synthesize a fluorescent internal DNA standard for automated fragment sizing. Biotechniques 2001;31:793-800.

  42. Bhattacharya A, Bhattacharya S, Joshi A, Ramachandran S, Ramaswamy R. Identification of parasitic genes by computational methods. Parasitol Today 2000;16:127-131.

  43. Mansfield ES, Blasband A, Kronick MN, Wrabetz L, Kaplan P, Rappaport E, et al. Fluorescent approaches to diagnosis of Lesch-Nyhan syndrome and quantitative analysis of carrier status. Mol Cell Probes 1993;7:311-324.

  44. Mansfield ES, Robertson JM, Lebo RV, Lucero MY, Mayrand PE, Rappaport E, et al. Duchenne/Becker muscular dystrophy carrier detection using quantitative PCR and fluorescence-based strategies. Am J Med Genet 1993;48:200-208.

  45. Mansfield ES, Vainer M, Harris DW, Gasparini P, Estivill X, Surrey S, et al.Rapid sizing of polymorphic microsatellite markers by capillary array electrophoresis. J Chromatogr A 1997;781:295-305.

  46. Sevilla T, Vilchez JJ. Different phenotypes of Charcot-Marie-Tooth disease caused by mutations in the same gene. Are classical criteria for classification still valid? Neurologia 2004;19:264-271.

  47. Palau F, Cuesta A, Pedrola L. Avances en la genética molecular de las neuropatías hereditarias. Rev Neurol 2002;35:246-253.

  48. López-Pison J, Rebage V, Baldellou-Vázquez A, Capablo-Liesa JL, Colomer J, Calvo MT, et al. Hereditary neuromuscular diseases in paediatrics. Our experience over the last 14 years. Rev Neurol 2005;41:145-150.

  49. Salinero-Paniagua E, Esteban-García A, Traba A, Palencia-Herrejón E, Garzo-Fernández C, Prieto-Montalvo J. Modified aspiration needle muscular biopsy in neuromuscular diseases. Use and advantages over open surgical biopsy. Rev Neurol 2004;39:821-825.

  50. Blair IP, Nash J, Gordon MJ, Nicholson GA. Prevalence and origin of the novo duplications in Charcot-Marie-Tooth disease type 1 A : First report of a de novo duplication with a maternal origin. Am J Hum Genet 1996;58:472-476.

  51. Xiao J, Tang B, Xia J. PCR in the gene diagnosis of Charcot-Marie-Tooth disease. Zhonghua Yi Xue Za Zhi 2001;81:138-141.

  52. Potocki L, Chen KS, Park SS, Osterholm DE, Withers MA, Kimonis V, et al. Molecular mechanism for duplication 17p11.2- the homologous recombination reciprocal of the Smith-Magenis microdeletion. Nat Genet 2000;24:84-87.

  53. Choi JR, Lee WH, Sunwoo IN, Lee EK, Lee CH, Lim JB. Effectiveness of realtime quantitative PCR compare to repeat PCR for the diagnosis of Charcot- Marie-Tooth Type 1A and hereditary neuropathy with liability to pressure palsies. Yonsei Med J 2005;46:347-352.

  54. Lin CY, Su YN, Lee CN, Hung CC, Cheng WF, Lin WL, et al. A rapid and reliable detection system for the analysis of PMP22 gene dosage by MP/ DHPLC assay. J Hum Genet 2006;51:227-235.

  55. Grandis M, Shy ME. Current Therapy for Charcot-Marie-Tooth Disease. Curr Treat Options Neurol 2005;7:23-31.




2020     |     www.medigraphic.com